Sign In
Buy THTX
$3.39
+0 (+0%)
At Close: Dec 24, 2025
TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone
Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets
01:00pm, Monday, 29'th Mar 2021
MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the d
Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors
07:30am, Wednesday, 24'th Mar 2021
MONTREAL, March 24, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innova
Theratechnologies (THTX) Enters Overbought Territory
07:34am, Tuesday, 23'rd Mar 2021
Theratechnologies (THTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation
11:00am, Saturday, 20'th Mar 2021
Data presented at ENDO 2021 Data presented at ENDO 2021
Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
04:30pm, Wednesday, 10'th Mar 2021
MONTREAL, March 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innova
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q4 2020 Results - Earnings Call Transcript
11:34pm, Saturday, 27'th Feb 2021
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q4 2020 Results - Earnings Call Transcript
Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference
04:43pm, Thursday, 25'th Feb 2021
MONTREAL, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat
Theratechnologies Announces Fourth Quarter and Fiscal Year 2020 Financial Results
07:30am, Thursday, 25'th Feb 2021
Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively
Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020
10:21am, Thursday, 11'th Feb 2021
MONTREAL, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovat
MONTREAL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat
MONTREAL, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and c
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
09:49am, Thursday, 14'th Jan 2021
MONTREAL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat
Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units
07:13pm, Monday, 11'th Jan 2021
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
